Details of the Drug Combinations

General Information of This Drug (ID: DMAB9QE)

Drug Name
Nivolumab   DMAB9QE
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [2]
Esophageal cancer 2B70 Phase 3 [3]
Gastric adenocarcinoma 2B72 Phase 3 [3]
Malignant pleural mesothelioma 2C26.0 Phase 3 [3]
Multiple myeloma 2A83 Phase 3 [3]
Recurrent glioblastoma 2A00.00 Phase 3 [3]
Small-cell lung cancer 2C25.Y Phase 3 [3]
Central nervous system lymphoma 2B33.5 Phase 2 [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
Diffuse large B-cell lymphoma 2A81 Phase 2 [3]
Follicular lymphoma 2A80 Phase 2 [3]
Prostate cancer 2C82.0 Phase 2 [3]
Ovarian cancer 2C73 Phase 1/2 [3]
Pancreatic cancer 2C10 Phase 1/2 [3]
Triple negative breast cancer 2C60-2C65 Phase 1/2 [3]
Chronic myelogenous leukaemia 2A20.0 Phase 1 [3]
Renal cell carcinoma 2C90 Application submitted [3]
Lung squamous cell carcinoma 2C25.2 Investigative [5]
⏷ Show the Full List of Indication(s)
Drug Type
Monoclonal antibody

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Ipilimumab + Nivolumab DCPE56X Ipilimumab Head and neck cancer; Mesothelioma; Renal cell carcinoma; Small-cell lung cancer; Solid tumour/cancer [6]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7335).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1
5 The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma. Molecules. 2021 Mar 5;26(5):1392.
6 FDA Drug Development and Drug Interactions